Effect of Exercise on Insulin Resistance (EFFORT)
Primary Purpose
Prediabetic State
Status
Terminated
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Current Recommendations Exercise Group
Intensive Exercise Group
Sponsored by
About this trial
This is an interventional prevention trial for Prediabetic State
Eligibility Criteria
Inclusion Criteria
- Aged 18 to 75 years.
Meets one of the three diagnostic criteria listed below (based on screening results or recorded result within one week of enrollment);
- Fasting plasma or whole blood glucose (fasting defined as no caloric intake for at least 8 hours): 100 ≤ 125 mg/dL (6.0-6.9 mmol/L)
- HbA1c of 5.7% - 6.4% (39 - 46 mmol/mol)
- 2-hour plasma glucose of 140-199 mg/dL (7.8-11.0 mmol/L) during an OGTT (as described by the WHO using a glucose load of 75 g anhydrous glucose dissolved in water)
- No clinically significant adverse exercise response during the maximal graded exercise test
Exclusion Criteria
- Weight loss diet program or weight change (>10%) within the past 6 months
- Daily physical activity of >10,000 steps per day (as measured during the interval between visits 1 and 2)
- Participates in deliberate structured exercise
- Pregnant or intending to become pregnant
- Cognitive or intellectual disability that prevents subject from providing informed consent or following protocol instructions.
- Unwillingness to participate in all study procedures
- Inability to give blood through multiple venous phlebotomies or to have an intravenous catheter
- BMI greater than 40 kg/m2
- Concurrent participation in another lifestyle modification trial
Diagnosis of diabetes based on any one of the following criteria:
- Fasting plasma or whole blood glucose ≥ 126 mg/dL (7 mmol/L)
- HbA1c of >6.5% (>47 mmol/mol)
- 2-hour plasma glucose ≥ 200 mg/dL (11.1 mmol/L) during an OGTT
Any pre-existing or newly discovered medical condition that is deemed likely to put the subject at risk of injury during this trial. This may include but is not limited to:
- Clinically relevant vascular or cerebrovascular event (e.g. stroke, recurrent transient ischemic attack (TIA), deep venous thrombosis or intracardiac thrombi, clinically significant edema within the previous 6 months
- Current use of anti-psychotic, anti-convulsant, anti-coagulant, sedative medication, or cognition-enhancing medications
- Current use of beta blockers (beta-adrenergic blocking agents)
- Current or previous use (within the past year) of the following medications: diabetes related medications or insulin; metformin; growth hormone; glucagon; dipeptidyl peptidase-4(DPP-4) inhibitors (saxagliptin, stigagliptin); glucagon-Like Peptide-1(GLP-1) mimetics (exenatide, liraglutide); sulfonylurea medication or other potential confounding medications
- Medical conditon which predetermines insulin resistance (e.g. Marfan syndrome / severe Polycystic ovary syndrome (PCOS) / Cushing syndrome etc.).
- Fasting triglycerides > 1000 mg/dL.
Sites / Locations
- Manchester University
- Move Lab
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Intensive Exercise Group
Current Recommendations Exercise Group
Arm Description
Behavioral
Behavioral
Outcomes
Primary Outcome Measures
A decrease in Insulin Resistance (IR) as measured by a change in IR.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01941277
Brief Title
Effect of Exercise on Insulin Resistance
Acronym
EFFORT
Official Title
Effect of Exercise on Insulin Resistance
Study Type
Interventional
2. Study Status
Record Verification Date
July 2016
Overall Recruitment Status
Terminated
Why Stopped
funding withdrawn
Study Start Date
August 2014 (undefined)
Primary Completion Date
March 2015 (Actual)
Study Completion Date
March 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alere San Diego
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the effect of exercise on Insulin Resistance (IR) in subjects who do not routinely exercise and who are at risk of developing diabetes (prediabetes).
It is estimated that approximately 30-90 people will participate in this study at three study sites in the United States and United Kingdom.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prediabetic State
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
3 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intensive Exercise Group
Arm Type
Experimental
Arm Description
Behavioral
Arm Title
Current Recommendations Exercise Group
Arm Type
Experimental
Arm Description
Behavioral
Intervention Type
Behavioral
Intervention Name(s)
Current Recommendations Exercise Group
Intervention Type
Behavioral
Intervention Name(s)
Intensive Exercise Group
Primary Outcome Measure Information:
Title
A decrease in Insulin Resistance (IR) as measured by a change in IR.
Time Frame
change between baseline and 6 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria
Aged 18 to 75 years.
Meets one of the three diagnostic criteria listed below (based on screening results or recorded result within one week of enrollment);
Fasting plasma or whole blood glucose (fasting defined as no caloric intake for at least 8 hours): 100 ≤ 125 mg/dL (6.0-6.9 mmol/L)
HbA1c of 5.7% - 6.4% (39 - 46 mmol/mol)
2-hour plasma glucose of 140-199 mg/dL (7.8-11.0 mmol/L) during an OGTT (as described by the WHO using a glucose load of 75 g anhydrous glucose dissolved in water)
No clinically significant adverse exercise response during the maximal graded exercise test
Exclusion Criteria
Weight loss diet program or weight change (>10%) within the past 6 months
Daily physical activity of >10,000 steps per day (as measured during the interval between visits 1 and 2)
Participates in deliberate structured exercise
Pregnant or intending to become pregnant
Cognitive or intellectual disability that prevents subject from providing informed consent or following protocol instructions.
Unwillingness to participate in all study procedures
Inability to give blood through multiple venous phlebotomies or to have an intravenous catheter
BMI greater than 40 kg/m2
Concurrent participation in another lifestyle modification trial
Diagnosis of diabetes based on any one of the following criteria:
Fasting plasma or whole blood glucose ≥ 126 mg/dL (7 mmol/L)
HbA1c of >6.5% (>47 mmol/mol)
2-hour plasma glucose ≥ 200 mg/dL (11.1 mmol/L) during an OGTT
Any pre-existing or newly discovered medical condition that is deemed likely to put the subject at risk of injury during this trial. This may include but is not limited to:
Clinically relevant vascular or cerebrovascular event (e.g. stroke, recurrent transient ischemic attack (TIA), deep venous thrombosis or intracardiac thrombi, clinically significant edema within the previous 6 months
Current use of anti-psychotic, anti-convulsant, anti-coagulant, sedative medication, or cognition-enhancing medications
Current use of beta blockers (beta-adrenergic blocking agents)
Current or previous use (within the past year) of the following medications: diabetes related medications or insulin; metformin; growth hormone; glucagon; dipeptidyl peptidase-4(DPP-4) inhibitors (saxagliptin, stigagliptin); glucagon-Like Peptide-1(GLP-1) mimetics (exenatide, liraglutide); sulfonylurea medication or other potential confounding medications
Medical conditon which predetermines insulin resistance (e.g. Marfan syndrome / severe Polycystic ovary syndrome (PCOS) / Cushing syndrome etc.).
Fasting triglycerides > 1000 mg/dL.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rick San George, PhD
Organizational Affiliation
Alere San Diego
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Michael Trenell, PhD
Organizational Affiliation
Newcastle University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Manchester University
City
Manchester
ZIP/Postal Code
M23 9QZ
Country
United Kingdom
Facility Name
Move Lab
City
Newcastle upon Tyne
ZIP/Postal Code
NE1 7RU
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
Effect of Exercise on Insulin Resistance
We'll reach out to this number within 24 hrs